Acacia Research Corporation — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. Acacia’s operating subsidiaries acquire or partner for patent rights, then license and enforce those rights, sometimes through litigation.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $130.9 million | $130.6 million |
| Operating income (loss) | $(62.2) million | $(82.9) million |
| Net income (loss) attributable to Acacia | $(66.0) million | $(56.4) million |
| Diluted loss per share | $(1.37) | $(1.18) |
| Cash provided by (used in) operating activities | $4.2 million | $(3.5) million |
| Cash, cash equivalents and short-term investments at year-end | $193.0 million | $256.7 million |
| Working capital at year-end | $172.8 million | $247.7 million |
FY 2014 operating costs and expenses were $193.0 million, including $57.2 million of patent amortization and $37.6 million of patent litigation and licensing expenses. No debt or committed credit lines were reported. Contractual obligations totaled $24.9 million, including $16.7 million of scheduled patent-investment payments due within one year and $8.2 million of operating leases.
Fourth quarter: Revenue was $31.0 million, compared with $15.1 million in Q4 2013; net loss attributable to Acacia was $16.2 million, versus $33.3 million. Quarterly results are unaudited and may fluctuate substantially.
Changes versus prior periods
- Annual revenue was essentially flat year over year, but remained 48% below FY 2012’s $250.7 million.
- FY 2014 net loss widened by $9.6 million from FY 2013 despite lower operating loss. Lower royalties and contingent legal fees, lower general and administrative expenses, and lower patent litigation costs were offset in part by higher patent amortization and a less favorable tax result.
- Operating cash flow improved by $7.7 million to positive $4.2 million. Licensee cash receipts fell to $117.0 million from $133.5 million; year-end receivables rose to $20.2 million from $6.3 million.
- Patent portfolio additions declined to 6 in 2014 from 25 in 2013. Management said it is shifting intake toward fewer, higher-quality portfolios; 2014 patent investment costs were $42.7 million, with a further $16.7 million accrued for payment in 2015.
- Quarterly dividends paid totaled $25.0 million in 2014, compared with $18.6 million in 2013. The board approved another $0.125-per-share quarterly dividend for payment in March 2015; future dividends remain discretionary.
Outlook, risks and unusual items
- Management expects cash, investments and anticipated operating cash flow to meet cash requirements through at least March 2016. No numerical revenue or earnings guidance was provided.
- Revenue depends on the timing and size of license agreements, negotiations, litigation outcomes and licensee reporting. Management does not seek smooth sequential revenue growth; licensing income may shift between periods.
- Two licensees each accounted for 22% of FY 2014 revenue. Three licensees represented approximately 30%, 17% and 15% of year-end receivables. This concentration creates collection and revenue-timing exposure.
- Patent litigation involves uncertain outcomes, extended timelines and potentially significant legal expense. Courts found two cases initiated in 2010 and 2011 “exceptional”; defendants requested a combined $2.8 million. Acacia accrued $1.5 million and subsidiaries appealed. The filing says ordinary-course claims and proceedings are not expected to materially affect consolidated results, but sanctions or fee awards could be material.
- FY 2014 included $3.5 million of patent impairment charges and a $1.5 million accrual for the court matters. The company recorded a full valuation allowance against net deferred tax assets; the FY 2014 tax provision was $3.9 million, while FY 2013 had a $22.0 million tax benefit.
- Key industry risks include changes in patent law and enforcement procedures, potential fee shifting, patent validity challenges, competition for portfolios, technology obsolescence, and impairment risk. Patent amortization is substantial, with $52.0 million estimated for 2015.
- Grant Thornton issued unqualified opinions on the financial statements and internal control over financial reporting as of year-end; management also concluded disclosure controls and internal control were effective.
Investor verification priorities
- Assess whether operating cash generation and $193.0 million of cash and investments can support litigation costs, portfolio investments, dividends and other commitments.
- Review the collectibility and timing of the $20.2 million receivable balance, particularly given licensee concentration.
- Track the appeals and potential exposure from the two exceptional-case rulings and any further fee or sanctions decisions.
- Evaluate the assumptions supporting patent portfolio values, future licensing prospects and the $286.6 million net patent asset balance, including scheduled amortization and impairment risk.
- Monitor revenue concentration, quarterly volatility, and whether the strategic shift toward higher-quality portfolios results in sustainable licensing revenue.
- Confirm the board’s future dividend decisions and the realizability of deferred tax assets subject to valuation allowances.